FDA sets meeting to review 6 speedy cancer drug approvals as evaluation widens

Published by W Butcher on

The Food and Drug Administration has scheduled a three-day virtual meeting in April to review six accelerated approvals given to cancer immunotherapies from Roche, Bristol Myers Squibb and Merck & Co. At the advisory panel, set for April 27 through 29, regulators, oncologists and patient advocates will discuss what the FDA should do about the six approvals. The drugs were cleared based on early results showing they kept tumors from spreading.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.